Skip to Content

Cosentyx Approval History

Cosentyx (secukinumab) is a selective interleukin-17A (IL-17A) inhibitor for the treatment of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.

Development History and FDA Approval Process for Cosentyx

DateArticle
Jan 15, 2016Approval Novartis Receives FDA Approval for Cosentyx (secukinumab) to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis
Jan 21, 2015Approval FDA Approves Cosentyx (secukinumab) for Plaque Psoriasis
Nov 10, 2014Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in Psoriatic Arthritis and Ankylosing Spondylitis
Oct 20, 2014FDA Advisory Committee Recommends Approval of Secukinumab for Plaque Psoriasis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide